These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26090600)

  • 1. Production and Characterization of New Anti-HER2 Monoclonal Antibodies.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):213-21. PubMed ID: 26090600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
    Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
    Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
    Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and characterization of new HER2 monoclonal antibodies.
    Vasconcellos FA; Aleixo PB; Stone SC; Conceição FR; Dellagostin OA; Aleixo JA
    Acta Histochem; 2013 Apr; 115(3):240-4. PubMed ID: 22901624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
    Yip YL; Smith G; Koch J; Dübel S; Ward RL
    J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
    Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
    Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein.
    Chua CL; Chan YF; Sam IC
    J Virol Methods; 2014 Jan; 195():126-33. PubMed ID: 24134938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
    Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
    Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
    Verma B; Hawkins OE; Neethling FA; Caseltine SL; Largo SR; Hildebrand WH; Weidanz JA
    Cancer Immunol Immunother; 2010 Apr; 59(4):563-73. PubMed ID: 19779714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
    Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
    Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
    Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
    Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.
    Olszewska W; Obeid OE; Steward MW
    Virology; 2000 Jun; 272(1):98-105. PubMed ID: 10873752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
    Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
    Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
    J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
    Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
    J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
    Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
    J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and characterization of a new chimeric antibody against HER2.
    Amiri MM; Jeddi-Tehrani M; Kazemi T; Bahadori M; Maddah M; Hojjat-Farsangi M; Khoshnoodi J; Rabbani H; Shokri F
    Immunotherapy; 2013 Jul; 5(7):703-15. PubMed ID: 23829622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.